• Explore /
  • Poster
  • / Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.

Neoadjuvant immuno-chemo-radiotherapy in operable esophageal and gastroesophageal junction adenocarcinoma with carboplatin, paclitaxel plus radiotherapy and avelumab (anti-PDL1 antibody): Neo-CREATE trial.

Abstract Poster

Authors

null

Amitesh Chandra Roy

Flinders University, Adelaide, SA, Australia

Amitesh Chandra Roy , Tim F Bright , Nimit Singhal , Matthew E. Burge , Eva Segelov , Andrew Mark Haydon , Lorraine A. Chantrill , Michael Michael , Caroline Connell , David Moffat , Richard John Woodman , Michael Michael , Erin Symonds , Timothy Jay Price , Alex Scott-Hoy , Alison Richards , Christos Stelios Karapetis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer - Local-Regional Disease

Clinical Trial Registration Number

ACTRN12619000288123

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr 4086)

DOI

10.1200/JCO.2024.42.16_suppl.4086

Abstract #

4086

Poster Bd #

66

Abstract Disclosures

Similar Posters

First Author: Mitsuho Imai

First Author: Zefei Jiang

First Author: Ronan Andrew Mc Laughlin

First Author: Nieves Martinez Chanza